Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06136884
Other study ID # A2A-O-004
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date November 2, 2023
Est. completion date January 27, 2027

Study information

Verified date May 2024
Source A2A Pharmaceuticals Inc.
Contact Dr. Sotirios Stergiopoulos, MD, CEO
Phone 718-570-5029
Email clinicaltrials@a2apharma.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.


Description:

The purpose of this study is to characterize the safety, tolerability including determination of maximum tolerated dose (MTD), and identify the recommended Phase 2 dose (RP2D). The study will also look at pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of AO-252 as a monotherapy in participants with advanced or metastatic triple negative breast cancer (TNBC), high- grade serous ovarian carcinoma (HGSOC), and endometrial cancer


Recruitment information / eligibility

Status Recruiting
Enrollment 144
Est. completion date January 27, 2027
Est. primary completion date October 28, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adults = 18 years of age. Patient has TNBC; OR platinum-resistant HGSOC, primary peritoneal cancer, and/or fallopian-tube cancer; OR serous endometrial cancer, as described below. 2. TNBC: 1. Histologically or cytologically confirmed metastatic or locally recurrent unresectable TNBC per American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) criteria. 2. TNBC must have TP53 mutation/loss and be relapsed/refractory to at least 1 line of systemic chemotherapy in the metastatic setting (excluding neoadjuvant or adjuvant chemotherapies) or be intolerant of existing therapy(ies). Prior exposure to an immune checkpoint inhibitor is allowed. 3. Platinum-resistant HGSOC, primary peritoneal cancer, and/or fallopian-tube cancer: 1. Histologically or cytologically confirmed diagnosis of metastatic or unresectable HGSOC, with TP53 mutation/loss, with platinum resistance defined as progression during or within 6 months of a platinum containing regimen, with no other standard treatment option available. Prior exposure to platinum-resistant recurrence therapy is allowed. 2. Patients whose tumors have progressed after at least 1 line of therapy for advanced/metastatic settings. 3. Systemic therapy with a PARP inhibitor will be counted as 1 line of therapy. Induction followed by maintenance will be counted as 1 line of therapy. 4. Serous endometrial cancer: a. Histologically or cytologically confirmed diagnosis of metastatic or recurrent unresectable serous endometrial cancer with TP53 mutation/loss and tumor must have relapsed/be refractory to at least 1 line of systemic therapy (including immune checkpoint inhibitors) but no more than 4 lines of systemic therapy in the metastatic/recurrent setting or be intolerant of existing therapy(ies) known to provide clinical benefit for their condition. 5. Measurable disease per RECIST v1.1 6. Adequate bone marrow reserve, cardiac, liver, and renal function: 1. Absolute neutrophil count (ANC) = 1,500/mm3 2. Platelet count = 100,000/mm3 3. Hemoglobin = 9 g/dL 4. Bilirubin = 1.5 × upper limit of normal (ULN) or direct bilirubin = ULN for patients with total bilirubin levels >1.5 × ULN 5. Alanine aminotransferase (ALT, SGPT) and aspartate aminotransferase (AST, SGOT) = 2.5 × ULN (= 5 × ULN if liver metastases are present) 6. INR = 1.5 × ULN unless patient is receiving anticoagulant therapy and PT or aPTT is within therapeutic range of intended use of anticoagulants 7. Serum creatinine = 1.5 ULN or creatinine clearance = 50 mL/min (by Cockroft Gault formula). 7. Female patients of child-bearing potential must have a negative serum pregnancy test and use at least 1 form of acceptable birth control method listed below as approved by the Investigator before initiating study treatment and for 3 months after the last dose of study drug. 1. Sterilization 2. Any hormonal contraceptives (non-CYP 3A4 inhibitors) associated with inhibition of ovulation 3. IUD (intrauterine device) or intrauterine hormone releasing system 8. Male patients must be sterilized or use a form of barrier contraception, such as condoms with spermicide, during the study and for 3 months after the last dose of study drug. 9. Life expectancy of = 3 months. 10. Ability to provide written informed consent. 11. An Eastern Cooperative Oncology Group (ECOG) performance status of = 1. Exclusion Criteria: 1. Patients with untreated or symptomatic brain metastases and/or leptomeningeal disease (exception: treated and stable brain metastases without symptoms for = 2 weeks after completion of treatment, image documentation is required, and the patient must not be taking steroids). 2. Patients with a previous history of another malignancy (other than cured basal cell or squamous cell carcinoma of the skin or cured in-situ carcinoma) within 3 years of study entry. 3. Patients with uncontrolled pleural effusions, pericardial effusion, or ascites that do not resolve. 4. Patients with gastrointestinal tract disease causing the inability to take oral medication (e.g., swallowing difficulties, malabsorption syndromes, extensive small bowel resection [> 100cm], gastric bypass surgery). 5. Pregnant or breast-feeding patients or any patient with child-bearing potential not using adequate contraception. 6. Known human immunodeficiency virus, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (excluding cured HBV and/or cured HCV infection). 7. Presence of any serious concomitant systemic disorders incompatible with the study in the opinion of the Investigator (e.g., uncontrolled congestive heart failure, active infection). 8. Radiation therapy to > 30% of bone marrow before study entry. 9. Patients who require chronic systemic steroid therapy (> 10 mg prednisone daily or equivalent) or those that are on any other form of immunosuppressive medication. 10. Patients with active autoimmune disease or with a documented history of autoimmune disease. 11. Patients with abnormal or clinically significant electrocardiogram (ECG) abnormality, including but not limited to a confirmed corrected QT interval using Fridericia's formula (QTcF) > 470 msec. 12. Patient has received systemic anticancer therapy within 3 weeks or 5 half-lives, whichever is shorter. 13. Patients must have recovered from all AEs due to previous therapies to = Grade 1 or baseline. 14. Any of the following conditions (on-study testing is not required): 1. Known HIV-infected patients unless on effective anti-retroviral therapy with an undetectable viral load within 6 months and no opportunistic infection within the past 12 months, or 2. Known or suspected hepatitis B if active infection (patients with chronic hepatitis B infection must have an undetectable HBV viral load on suppressive therapy, if indicated; positive surface antibody alone is not an exclusion), or 3. Known or suspected hepatitis C infection that has not been treated and cured unless currently on treatment with an undetectable viral load. 15. Administration of strong or moderate cytochrome (CYP) 3A4 inhibitors and inducers within 14 days or 5 half-lives (whichever is shorter) prior to the administration of study drug.

Study Design


Intervention

Drug:
AO-252
AO-252 will be administered oral tablets daily

Locations

Country Name City State
United States Mary Crowley Cancer Research Dallas Texas
United States Next Oncology -Virginia Fairfax Virginia
United States The University of Texas M.D. Anderson Cancer Center Houston Texas
United States Oklahoma Univeristy Oklahoma City Oklahoma

Sponsors (1)

Lead Sponsor Collaborator
A2A Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety Assessments [Dose escalation] Incidence of Dose Limiting Toxicities (DLTs) in DLT-evaluable subjects 12 months
Primary Safety Assessments [Dose escalation] Identify the maximum tolerated dose and the doses for expansion 12 months
Primary Safety Assessments [Dose escalation and Dose expansion] Number of participants with Serious Adverse Events (SAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 30 months
Primary Safety Assessments [Dose escalation and Dose expansion] Number of participants with Treatment-related Adverse Events (AEs) graded per NCI-CTCAE version 5.0 30 months
Primary Safety Assessments [Dose escalation and Dose expansion] Number of participants with Treatment-Emergent AEs (TEAEs) graded per NCI-CTCAE version 5.0 30 months
Primary Safety Assessments [Dose escalation and Dose expansion] Number of participants with Dose Interruptions and Permanent Treatment Discontinuations 30 months
Secondary Antitumor Activity of AO-252 [Dose escalation and Dose expansion] Determine the objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 30 months
Secondary Antitumor Activity of AO-252 [Dose escalation and Dose expansion] Determine the disease control rate (DCR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 30 months
Secondary Antitumor Activity of AO-252 [Dose escalation and Dose expansion] Determine the time to response (TTR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. 30 months
Secondary Antitumor Activity of AO-252 [Dose escalation and Dose expansion] Determine the time to progression (TTP) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 30 months
Secondary Pharmacokinetic Profile of AO-252 [Dose escalation and Dose expansion] Identity the maximum concentration (Cmax) on Day 1 of Cycle 1-3 and D14 and 28 of Cycle 1 30 months
Secondary Pharmacokinetic Profile of AO-252 [Dose escalation and Dose expansion] Identify the area under the curve (AUC) on Day 1 of Cycle 1-3 and D14 and 28 of Cycle 1 30 months
Secondary Pharmacokinetic Profile of AO-252 [Dose escalation and Dose expansion] Identify the time to maximum concentration (Tmax) on Day 1 of Cycle 1-3 and D14 and 28 of Cycle 1 30 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05796518 - Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors N/A
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06463028 - Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer Phase 2
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Completed NCT03820024 - MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback N/A
Active, not recruiting NCT05082025 - Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations Phase 2
Active, not recruiting NCT00587886 - Estrogen, Diet, Genetics and Endometrial Cancer
Completed NCT05378152 - Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity N/A
Suspended NCT05124743 - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Recruiting NCT04569773 - Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Not yet recruiting NCT05998798 - Revealing Engagement Patterns Among Endometrial Cancer Patients
Not yet recruiting NCT06366347 - ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab Phase 2
Not yet recruiting NCT06073184 - Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium Phase 2
Terminated NCT02907073 - Positron Emission Tomography (PET) Imaging Studies With NIS Reporter Phase 1/Phase 2
Completed NCT02413606 - ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More? N/A